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clinical trials to date are largely hindered within airway mucus,
which limits their access to, and transduction of, the underlying
airway epithelium prior to clearance from the lung. Here, we
discovered that adeno-associated virus (AAV) serotype 6 was
able to rapidly diffuse through mucus collected from cystic
fibrosis (CF) patients, unlike previously tested AAV serotypes.
A point mutation of the AAV6 capsid suggests a potential
mechanism by which AAV6 avoids adhesion to the mucus
mesh. Significantly greater transgene expression was achieved
with AAV6 compared to a mucoadhesive serotype, AAV1, in
air-liquid interface cultures of human CF bronchial epithelium
with naturally secreted mucus or induced mucus hypersecre-
tion. In addition, AAV6 achieved superior distribution and
overall level of transgene expression compared to AAV1 in
the airways and whole lungs, respectively, of transgenic mice
with airway mucus obstruction. Our findings motivate further
evaluation and clinical development of AAV6 for inhaled gene
therapy.
INTRODUCTION
Past clinical trials testing viral gene vectors, including adenovirus
(AdV) and adeno-associated virus (AAV) serotype 2, for inhaled
gene therapy have failed to provide clinically significant benefits.
These disappointing outcomes have been attributed to inefficient
gene transfer to airway epithelium and generation of therapy-inacti-
vating host immune responses.1 Accordingly, recent advances in viral
vector engineering have focused on enhancing the transduction of
airway epithelium2–10 and reducing immunogenicity.11,12 Whereas
underappreciated in early clinical studies, airway mucus has been
recently recognized as another critical biological barrier to inhaled
therapeutics.13–21 The airway epithelium is protected by a secreted296 Molecular Therapy: Methods & Clinical Development Vol. 9 June 20
This is an open access article under the CC BY-NC-ND license (httpmucus gel layer that traps most inhaled foreign materials, including
gene vectors, and facilitates their removal from the airways via mucus
clearance mechanisms.13,22,23 In previous studies, we found that
many clinically tested and commonly used viral vectors, including
AdV, AAV1, AAV2, and AAV5, bind adhesively to human airway
mucus,24,25 impeding access to the epithelium that is required for
successful transduction.
Recent studies comparing AAV serotypes for inhaled application
revealed that AAV6 provided superior gene transfer efficacy in vitro
and in vivo to other serotypes.2,26–28 However, the underlying mecha-
nisms are not fully understood, with one report suggesting a potential
role of its ability to escape the proteasome degradation pathway.26 In
addition, many prior studies have been conducted using in vitro and
in vivomodels that lack the lung pathophysiology similar to that of pa-
tients withmuco-obstructive lung diseases, such as cystic fibrosis (CF),
chronic obstructive pulmonary disease (COPD), and asthma. To this
end, we sought to evaluate the performance of AAV6 in the lung using
physiologically relevant experimental conditions, including human
CF sputum, a mucus-covered air-liquid interface (ALI) culture of hu-
man CF airway epithelium, and an advanced transgenic mouse model
closely mimicking the lung environment found in muco-obstructive
lung diseases. Using multiple particle tracking (MPT), we first inves-
tigated whether AAV6 was capable of avoiding entrapment within18 ª 2018 The Authors.
://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. AAV Diffusion in Spontaneously Expectorated CF Sputum
(A) Representative trajectories of AAV1 and AAV6 in sputum samples from 3 CF
patients. Trajectories show 10 s of AAV motions. Color bar indicates the time (t) of
the trajectory in seconds. The scale bar represents 1 mm. (B) Box-and-whisker
plots of MSD1 s of AAV1 and AAV6 in sputum samples collected from 8 individual
CF patients are shown. Maximum whisker length is 1.5 times the interquartile
range; outliers are shown as dots. (C) Representative trajectories of AAV1, AAV6,
and AAV6-K531E in CF sputum are shown. Trajectories show 10 s of AAVmotions.
Color bar indicates the time (t) of the trajectory in seconds. The scale bar
represents 1 mm. (D) Box-and-whisker plots of MSD1 s for AAV1, AAV6, and AAV6-
K531E in all patient samples tested are shown. Outliers are not shown. *p < 0.05;
Mann-Whitney test.
www.moleculartherapy.orgthe mucus meshwork of CF sputum, unlike previously tested AAV se-
rotypes.24,25We then determined the impact of the airwaymucus bar-
rier on the ability of AAV6 to mediate transgene expression in airway
epithelium in vitro and in vivo and compared AAV6 to AAV1, a sero-
type shown to outperform the clinically testedAAV229,30 but unable to
efficiently penetrate human CF sputum.25
RESULTS
AAV Diffusion in Freshly Collected CF Sputum
To assess the abilities of different AAV vectors to penetrate
human airway mucus, we measured using MPT the diffusion ratesMolecuof Alexa Fluor 647 (AF647)-labeled AAV in freshly collected sputum
samples spontaneously expectorated by CF patients. The percent
solids content and mucin concentration of collected sputum samples
were 7.4 ± 4.9% and 5.9 ± 1.6 mg/mL, respectively, in good agree-
ment with previously reported values.31,32 We have previously
confirmed that our method of AF647 labeling does not significantly
alter the natural surface property and transduction efficiency of
AAV.25 Consistent with our prior observation,25 AAV1 displayed
highly confined trajectories, indicating their entrapment within
CF sputum. In contrast, AAV6 traveled far greater distances over
time (Figure 1A). Quantitatively, AAV6 consistently exhibited
greater diffusion rates, measured by mean squared displacement
at a timescale of 1 s (MSD1s), compared to AAV1 in sputum sam-
ples collected from 8 different CF patients (Figure 1B). MSD1s rep-
resents the average squared distance individual AAVs travel within
a 1-s time interval and is directly proportional to their diffusion
rates.33 Based on the median of MSD1s, AAV6 diffusion in CF
sputum was enhanced by 3- to 10-fold in comparison to AAV1.
Of note, we found that the diffusion rate of AAV6 was comparable
to that of a synthetic gene delivery nanoparticle previously
confirmed to efficiently penetrate CF sputum19 (Figure S1). In or-
der to further explore the differences in diffusion behaviors of
AAV1 and AAV6 in CF sputum, we measured the diffusion rate
of an AAV6 mutant, AAV6-K531E, which has been previously
shown to confer AAV6 with an AAV1-like binding affinity to gly-
cans.34 The diffusion rates of AAV6-K531E in 5 different CF
sputum samples were significantly lower than those of wild-type
AAV6 and comparable to those of wild-type AAV1 (Figures 1C
and 1D). We found that diffusion rates of AAV1 and AAV6 did
not significantly correlate with solids content (i.e., percent dry
weight) of sputum samples (R2 = 0.05), consistent with our prior
observation with AAV2.25
Impact of Apical Mucus on In Vitro AAV Transduction
Based on the significantly enhanced diffusion rates of AAV6
compared to AAV1 in CF sputum (Figure 1), we next sought to
determine the impact of secreted mucus on the abilities of different
AAV vectors to penetrate to the underlying airway epithelial cells
and mediate transgene expression in vitro. We first examined
in vitro transduction efficiency of AAV1, AAV6, and AAV6-
K531E packaged with self-complementary EGFP gene (scAAV-
EGFP) in human CF bronchial epithelial immortalized (CFBE41o-)
cells, derived from a F508del homozygous CF patient, grown at an
ALI where cells are differentiated into a mucus-secreting lung
airway epithelium. Once fully differentiated, AAV-mediated GFP
transgene expression was evaluated 2 weeks post-infection using
confocal microscopy (Figures 2A–2C). We found that AAV6-
treated CFBE41o- cultures exhibited 2-fold greater coverage,
defined as the total reporter-positive area divided by the total
cell-covered surface area, and overall level of GFP transgene expres-
sion compared to AAV1-treated cultures, whereas both the
coverage, and overall level were comparable between AAV6-
K531E- and AAV1-treated cultures (Figures 2D and 2E). We then
repeated the experiment using CFBE41o- ALI cultures treated tolar Therapy: Methods & Clinical Development Vol. 9 June 2018 297
Figure 2. In Vitro Transgene Expression in Human
CFBE41o- ALI Cultures
(A–C) Representative images of CFBE41o- ALI cultures
transduced with (A) AAV1, (B) AAV6, and (C) AAV6-
K531E. The scale bar represents 50 mm. (D and E) Image-
based quantification of AAV-mediated GFP transgene
expression in terms of (D) overall level and (E) relative
coverage in CFBE41o- ALI cultures (n = 6) is shown.
(F) Mucin contents of CFBE41o- ALI cultures before and
after CSS treatment are shown. (G and H) Representative
images of CFBE41o- ALI cultures transduced with (G)
AAV1 and (H) AAV6 where cultures were pretreated
overnight with CSS are shown. (I and J) Image-based
quantification of AAV-mediated GFP transgene expres-
sion in terms of (I) overall level and (J) relative coverage
in CSS-pretreated CFBE41o- ALI cultures (n = 6) is
shown. *p < 0.05; Student’s t test (F) or one-way ANOVA
(D, E, I, and J).
Molecular Therapy: Methods & Clinical Developmentinduce mucus hypersecretion. Mucus hypersecretion was established
by incubating the cultures overnight with CF sputum supernatant
(CSS) solution rich in pro-inflammatory cytokines, such as inter-
leukin-1b (IL-1b), neutrophil elastase, and tumor necrosis factor
a (TNF-a),35 which has been previously shown to induce mucus
hypersecretion in human airway epithelial ALI cultures.36 Mucus
hypersecretion was confirmed by measuring the quantity of mucin
collected from the apical surfaces of CFBE41o- cultures where the298 Molecular Therapy: Methods & Clinical Development Vol. 9 June 2018mucin level was 3-fold greater in CSS-
treated cultures than in untreated control
cultures (Figure 2E). Subsequently, we com-
pared the transduction efficiency of apically
administered AAV1 and AAV6 in CSS-treated
versus untreated CFBE41o- cultures. The
AAV1-mediated coverage and overall level of
GFP transgene expression were significantly
reduced in CSS-treated CFBE41o- cultures
compared to untreated cultures, whereas
AAV6 retained those readouts regardless of
the CSS-induced mucus hypersecretion (Fig-
ures 2F–2J).
To further test the effect of secreted mucus
on AAV transduction, we evaluated AAV
transduction in primary CF human bronchial
epithelial (HBE) cells harvested from F508del
homozygous CF patients, grown at an ALI
with or without the removal of apically
secreted mucus. We found that, whereas the
coverage and overall level of GFP transgene
expression mediated by AAV1 was significantly
enhanced by washing the apical mucus with
PBS, mucus removal did not affect the readouts
when treated with AAV6 (Figure 3). Of
note, the removal of apically secreted mucusrestored AAV1-mediated transduction to levels comparable to
AAV6 (Figure 3).
In VivoAAV Transduction in aMouseModel ofMuco-obstructive
Lung Disease
To determine whether the mucus-penetrating property of AAV6
led to enhanced in vivo lung gene transfer, we compared
the transduction efficiencies of AAV1 and AAV6 following
Figure 3. In Vitro Transgene Expression in Primary CF HBE ALI Cultures
(A–D) Representative images of GFP expression in primary CFHBE ALI cultures 2 weeks post-AAV transduction. Prior to the treatment, cultures were either left unwashed (no
wash) or washed by PBS for the removal of the apically secretedmucus layer (PBSwash). The following conditions are shown: AAV1-treated HBE culture either unwashed (A)
or washed (B) with PBS and AAV6-treated HBE culture either unwashed (C) or washed (D) with PBS. The scale bar represents 50 mm. (E and F) Image-based quantification of
AAV-mediated GFP transgene expression in terms of (E) overall level and (F) relative coverage in primary CFHBE ALI cultures with (+) or without () PBSwash (n = 3) is shown.
*p < 0.05; one-way ANOVA.
www.moleculartherapy.orgadministration via an aerosol-generating microsprayer to the
lungs of Scnn1b-Tg mice overexpressing the b-subunit of the
epithelial sodium channel (bENaC) in the airways. Scnn1b-Tg
mice spontaneously develop disease symptoms reminiscent of
muco-obstructive lung diseases, such as mucus hyperconcentra-
tion/plugging, chronic airway inflammation, and airspace enlarge-
ment.37,38 We confirmed the presence of mucus plugs in the
airways of Scnn1b-Tg mice via immunohistochemistry, which was
also distinguished through luminal DAPI staining of immune cells
and DNA found within mucus plugs (Figure S2). For in vivo
transduction studies, 2  1010 AAV1 or AAV6 packaged with
single-stranded firefly luciferase-YFP fusion gene (ssAAV-Fluc-
YFP) in 50 mL PBS was administered into the lungs of Scnn1b-
Tg mice.
The lung distribution of YFP transgene expression was visualized
2 weeks post-infection with AAV1 or AAV6, as shown in the
representative confocal micrographs of proximal and distal airways
(Figures 4A–4H). The relative coverage of YFP transgene expression
in the airway and airspace was quantitatively assessed using
a custom-written MATLAB software. In analyzing different,
randomly selected regions of the airways and airspace, we observed
a significantly greater YFP coverage in the mucus-covered/plugged
airways (Figure S2A) of Scnn1b-Tg mice that intratracheally
received AAV6 (28%), compared to the mice that received dose-
matched AAV1 (13%; Figures 4B, 4D, and 4I). There was no signif-
icant difference in YFP coverage following the treatment with AAV6
(5%) and AAV1 (3%) in the airspace devoid of mucus secretion
(Figures 4I and S2B). We also determined the luciferase activity
of the whole-lung homogenates, an indicator of overall level of
reporter transgene expression, from AAV1- and AAV6-treated
Scnn1b-Tg mice, which revealed an 2-fold greater biolumines-
cence intensity in the lungs of AAV6- versus AAV1-treated
Scnn1b-Tg mice (Figure 4J).MolecuDISCUSSION
We have discovered that AAV6 is capable of efficiently diffusing
through human CF sputum (i.e., mucus), which presents a critical
extracellular barrier to effective inhaled gene therapy. In vitro studies
in transformed and primary CF airway epithelial ALI cultures
revealed that AAV6 gene transfer efficacy was not affected either by
the presence of an endogenously secreted mucus layer or by induced
mucus hypersecretion. In contrast, AAV1 transduction was markedly
inhibited by both steady-state or induced mucus, presumably as a
result of its inability to penetrate this barrier. The mucus-penetrating
property of AAV6 was further confirmed in vivo. Inhaled AAV6
provided widespread and high-level transgene expression in the
mucus-covered/plugged airways and the whole lungs, respectively,
of a mouse model with airway mucus obstruction. This result agrees
with our prior observations using synthetic mucus-penetrating drug
and gene delivery nanoparticles that, unlike conventional mucoadhe-
sive particles, exhibited widespread distribution and/or transgene
expression in mouse lungs.14,17–19,39 Importantly, the inhaled
AAV6 mediated roughly 30% airway coverage of transgene expres-
sion, which is comparable to the percentage of human CF airway
epithelial cells with cystic fibrosis transmembrane conductance
regulator (CFTR) transgene expression (25%) that was previously
shown to be sufficient to restore normal mucus transport rates
in vitro.40 Overall, efficient mucus penetration is likely a crucial mech-
anism by which AAV6may achieve therapeutically relevant lung gene
transfer.
In contrast to our observations, mucin was previously shown not to
inhibit AAV1 transduction in vitro.34 The discrepancy is likely due
to the markedly lower mucin concentrations employed in this earlier
study (%0.5 mg/mL),41 which is about an order of magnitude or
more lower than the concentrations in naturally or pathologically
secreted airway mucus collected from human subjects or ALI cultures
of primary CF HBE cells.31,42–45 It should be noted that, unlike anlar Therapy: Methods & Clinical Development Vol. 9 June 2018 299
Figure 4. In Vivo Transgene Expression in the Lungs of Scnn1b-Tg Mice following Intratracheal Administration of AAV1 or AAV6
(A–H) Representative images of YFP expression (green) in the proximal (A–D) and distal airways/airspace (E–H). Confocal images of the proximal lung tissues from AAV1-
treated mice showing cell nuclei only (A) or with YFP transgene expression (B) and from AAV6-treated mice showing cell nuclei only (C) or with YFP transgene expression (D).
Confocal images of the distal lung tissues from AAV1-treated mice showing cell nuclei only (F) or with YFP transgene expression (G) and from AAV6-treated mice showing cell
nuclei only (G) or with YFP transgene expression (H).Cell nuclei are stained with DAPI (blue). Regions of the airway lumen where mucus plugs were observed are outlined in
red. The scale bar represents 200 mm. (I) Image-based quantification of YFP expression coverage is shown (n = 3 mice with 3 or 4 lung sections per mouse). (J) Luciferase
expression mediated by AAV1 or AAV6 quantified for whole-lung homogenates is shown (n = 6 mice). *p < 0.05; Student’s t test.
Molecular Therapy: Methods & Clinical Developmentaqueous mucin solution, a mucus gel can trap nano-sized objects,
such as AAV, via multivalent adhesive interactions as well as steric
obstruction.14,16 We also showed that, out of the 6 different capsid
residues between AAV1 and AAV6, a single-amino-acid K-to-E sub-
stitution at the 531 position of the AAV6 capsid caused the mutant
AAV6 (i.e., AAV6-K531E) to behave like AAV1,34 a finding
confirmed in airway mucus in vitro and ex vivo. We have previously
demonstrated that heparan sulfate (HS) binding may be at least
partially responsible for the adhesion of AAV2 to CF sputum.25 How-
ever, it is unlikely the case here, as it has been shown previously that
AAV6 binds to HS, whereas AAV1 and AAV6-K531E do not.34,46
These findings suggest that glycan-mediated entrapment mechanisms
may vary among AAV serotypes. In future studies, we aim to further
explore the nature of interactions between different AAV serotypes
and the glycans present on airway mucins.
The results of this study demonstrate the importance of using preclin-
ical models that mimic key pathophysiological conditions of patients
affected withmuco-obstructive lung diseases in evaluating the efficacy
of inhaled gene therapy. Ex vivo and in vitro experiments were
designed to evaluate the ability of AAV6 to overcome pathological
human airway mucus (i.e., CF sputum) and subsequently achieve
efficient transduction of human airway epithelium. Past studies
comparing the gene transfer efficacy of different AAV serotypes in
human ALI cultures may have been affected by the large volumes
(50–200 mL)2,3,47–49 applied on the apical surface during AAV admin-
istration, which dilute and potentially alter the barrier properties of
apically secreted mucus. We thus used a small volume (i.e., 5 mL) in
our experiments to minimize this issue. Most preclinical in vivo
studies have also been conducted using healthy animals lacking
critical pathological features in the lung.16 In contrast, we evaluated
the in vivo gene transfer efficacies of AAV serotypes possessing300 Molecular Therapy: Methods & Clinical Development Vol. 9 June 20different abilities to penetrate the airway mucus barrier using an
established animal model of CF and COPD characterized by airway
mucus plugging.
Future studies should address the persistence of transgene expression
as well as the ability to readminister AAVwithout concern of therapy-
inactivating immunogenicity. Toward this end, development and/or
identification of a library of AAV vectors that possess the mucus-
penetrating property while retaining high-level transduction effi-
ciency would allow for serial vector administration for life-long
therapeutic effects. In summary, we have demonstrated that the abil-
ity of AAV6 to penetrate the mucus barrier is a critical mechanism by
which it achieves robust gene transfer to the lung airways. Our results
underscore the importance of vectors used in inhaled gene therapy to
overcome the mucus barrier, which is particularly reinforced in
patients with muco-obstructive lung diseases.
MATERIALS AND METHODS
Production of Recombinant AAV Gene Vectors and Fluorescent
Labeling
Recombinant AAV1, AAV6, and an AAV6 mutant, AAV6-K531E
vectors were packaged with either self-complementary EGFP
(scAAV-EGFP) or single-stranded firefly luciferase-YFP fusion
(ssAAV-Fluc-YFP) gene as described previously.50,51 Both reporter
transgenes are expressed under the control of the ubiquitous chicken
b-actin promoter (CBA). To engineer AAV6-K531E, a two-step PCR
with reading-proof Turbo Pfu Polymerase (Stratagene) was used on
plasmid pACGr2/c6 to introduce a single mutation;34,52 primers
were designed to make a change in an amino acid coding triplet
from lysine (K; codon: AAG) to glutamic acid (E; codon: GAG) at
531 position of AAV capsid. The titers of DNase-I-resistant vector
particles were determined by qPCR using the primer pair specific18
www.moleculartherapy.orgfor the CBA promoter, F-50-TCCCATAGTAACGCCAATAGG-30
and R-50-CTTGGCATATGATACACTTGATG-30, and SYBR
GreenER PCRMaster Mix (Invitrogen). Of note, two separate batches
of AAV vectors were constructed and used for in vitro and in vivo
transduction studies to ensure reproducibility. For visualization
and tracking of individual viruses, AAV was labeled with the
amine-reactive fluorescent dye, Alexa Fluor 647 carboxylic acid suc-
cinimidyl ester (AF647; Life Technologies), as previously described.25
AF647-labeled AAVs were stored at 80C and thawed on ice prior
to use.
Formulation of Synthetic Mucus-Penetrating Gene Delivery
Nanoparticles
For comparison with AAV diffusion in CF sputum, synthetic mucus-
penetrating gene delivery nanoparticles were formulated as described
previously.19 Briefly, 5 kDa methoxy polyethylene glycol (PEG)
N-hydroxysuccinimide (Sigma-Aldrich) was conjugated to 25 kDa
branched polyethylenimine (PEI) (Sigma-Aldrich) to yield PEG5k–
PEI copolymer. Nanoparticles were formed by the dropwise addition
of 9 or 10 volumes of 0.2 mg/mL GFP-encoding plasmid DNA
controlled by the cytomegalovirus promoter (Clontech) to 1 volume
of a swirling polymer solution containing 25% unmodified PEI and
75% PEG5k–PEI copolymer, at an optimized nitrogen to phosphate
ratio of 6. Twenty percent of the plasmid DNA used to assemble
nanoparticles was fluorescently labeled by Cy3 dye using the
Mirus Label IT Tracker Intracellular Nucleic Acid Localization Kit
(Mirus Bio).
CF Sputum Sample Collection and Biochemical Assay
CF sputum samples were collected under written informed consent,
in accordance with the Johns Hopkins Institutional Review Board
(IRB). Spontaneously expectorated sputum samples were collected
from patients visiting the Adult Cystic Fibrosis Center at Johns Hop-
kins University. Particle-tracking experiments were conducted using
samples stored at 4C immediately after collection for up to 24 hr,
based on our prior confirmation that the barrier properties of freshly
collected sputum are maintained in this condition.14,31 To reduce the
effects of salivary contamination, any sample with a visible quantity of
saliva was excluded. Patients involved in this study received no mu-
colytics other than Pulmozyme (i.e., dornase alfa) and/or hypertonic
saline as part of their standard treatment regimen. Further informa-
tion on the demographics of patients included in the study can be
found in the supplement.
The percent solids content and mucin concentration of sputum
samples were determined using previously reported methods.31 For
solids content, sputum samples were frozen in liquid N2 and placed
in a lyophilizer (FreeZone 4.5 Plus; Labconco) for at least 12 hr to
completely extract water within individual samples. The percent
solids content is defined as the ratio of mucus mass before and after
the lyophilization. Mucin concentration was determined based on the
reaction between 2-cyanoacetamide (Sigma-Aldrich) with O-linked
glycoproteins (i.e., mucin) followed by a fluorometric assay, as
previously described.31MolecuMultiple Particle Tracking in CF Sputum
The motions of AAV or synthetic mucus-penetrating gene delivery
nanoparticles in sputum were tracked by fluorescent video micro-
scopy and quantified by MPT analysis using a software custom-
written in MATLAB (MathWorks), as previously reported.25,33
In Vitro Transduction
The CFBE41o- cell line53 (a gift fromDrs. Cebotaru andGuggino from
JohnsHopkinsUniversity) andprimaryCFhumanbronchial epithelial
cells expressing the F508del mutant CFTR (CF HBE) were used for
in vitro transduction studies. The University of Alabama at Birming-
ham IRB approved the use of primary cells. CFBE41o- cells were grown
inminimumessentialmediawith 10% fetal bovine serum,L-glutamine,
penicillin/streptomycin, and puromycin (5 mg/mL). Primary CF HBE
cells were expanded using co-culture with irradiated fibroblasts
(R&D Systems) and conditional reprogramming via media containing
a rho-associated protein kinase inhibitor.54,55 CFBE41o- or primary CF
HBE cells were grown in 0.33 cm2 polyester membrane transwell in-
serts (Corning) at an ALI for 4–6 weeks until terminally differentiated.
Once theALIwas established, CFBE41o- or primary CFHBE cells were
maintained in the above-described growth media or PneumaCult-ALI
Maintenance Medium (STEMCELL Technologies), respectively. A
5-mL suspension of 2  109 AAV vector genomes, either AAV1,
AAV6, or AAV6-K531E, packaged with a gene encoding EGFP (i.e.,
scAAV-EGFP)was administered to the apical surface of the fully differ-
entiatedALI cultures at aMOI of 5,000 to evaluate in vitro transduction
efficiency. After an overnight incubationwith AAV, 100 mL of PBS was
added to the apical chamber of inoculated cultures, incubated for
30 min at 37C, and subsequently washed via aspiration.
We adapted a previously reported protocol to induce mucus hyperse-
cretion in CFBE41o- ALI cultures.36 Briefly, 5 mL of CSS was added to
both the apical and basolateral compartments and incubated over-
night. The CSS solution was prepared by high-speed centrifugation
(21,000  g) for 1 hr of 2.5 mL sputum pooled from 5 CF patients,
followed by filtration through a 0.2-mm ELF spin-filter (Molecular
Probes). Apical mucin content of CFBE41o- ALI cultures was fluoro-
metrically determined by the identical method used for the analysis of
CF sputum. To remove apically secreted mucus from primary CF
HBE ALI cultures, the apical chamber was incubated with 100 mL
of PBS at 37C for 30 min, followed by removal via aspiration. GFP
transgene expression was imaged using a confocal LSM 510 micro-
scope (Zeiss) at 10 and 20 magnification and quantified using a
custom-written software in MATLAB. To avoid artifacts presented
by differences in focus between images, we used automated focusing
(available in Zeiss Zen software) of DAPI nuclear staining and
captured all images at this focal plane. Six or more randomly selected
image fields were taken of each insert and used for quantification. The
percentage of GFP coverage was defined as the GFP-positive area
divided by the total cell-covered surface area, and the total GFP inten-
sity was quantified as the average of total pixel intensity units for each
dataset. Prior to quantitative analysis, all images were normalized by
fluorescence of untreated control ALI cultures to eliminate the contri-
bution of autofluorescence.lar Therapy: Methods & Clinical Development Vol. 9 June 2018 301
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All animals were treated in accordance with the policies and
guidelines of the Johns Hopkins University Animal Care and Use
Committee. Four-week old, congenic C57BL/6N transgenic mice
with airway-specific overexpression of the epithelial sodium channel
b-subunit (bENaC, gene Scnn1b; i.e., Scnn1b-Tg mice)37 were used
for in vivo transduction studies. To evaluate the distribution and
overall level of transgene expression in the lungs of Scnn1b-Tg
mice, a 50-mL solution of 2 1010 AAV packaged with a gene encod-
ing luciferase-YFP fusion protein (i.e., ssAAV-Fluc-YFP) was deliv-
ered intratracheally using a microsprayer (MicroSprayer Aerosolizer
Model IA-1C; Penn-Century; n = 3 and 6 mice per group for assess-
ing the distribution and overall level of transduction, respectively).
Animals were sacrificed 2 weeks post-administration to determine
the distribution of YFP transgene expression in airways/airspace as
well as luciferase activity of whole lung homogenates, a measure of
overall transgene expression level. For the distribution study,
lungs were harvested, flash-frozen in optimum cutting temperature
(OCT) compound, and cryosectioned using a CM1950 cryostat
(Leica Biosystems). Slides were immunologically stained using
a AF488-conjugated GFP monoclonal antibody (Santa Cruz
Biotechnology) and DAPI and subsequently imaged using a confocal
LSM 510 microscope under 10 and 20 magnification. Four or
more randomly selected image fields were taken from 3 lung tissue
sections showing regions of the airways and airspace (i.e., total of
at least 12 images per animal) for quantifying the distribution of
transgene expression. To quantitatively assess the coverage of YFP
transgene expression in airways/airspace, custom software written
in MATLAB was used where images were blinded and airway
regions were manually determined based on DAPI staining. The
boundaries of airway and non-airway regions (i.e., anywhere outside
of selected airway regions) were further refined using automated
image thresholding. Percentage of YFP coverage was defined as the
YFP-positive airway or airspace area divided by the total area of a
respective compartment. Prior to quantitative analysis, all images
were normalized by fluorescence of untreated Scnn1b-Tg lung tissue
to eliminate the contribution of autofluorescence. To directly visu-
alize mucus plugs in the airways of Scnn1b-Tg mice, slides were
immunologically stained with anti-MUC5B (Santa Cruz Biotech-
nology; 5B#19-2E:sc-21768) and anti-MUC5AC (Thermo Fisher;
MA5-12178) antibodies. For fluorescent tagging of MUC5AC and
MUC5B, a biotinylated anti-mouse immunoglobulin G (IgG)
(Sigma-Aldrich) was used as a secondary antibody, followed by a
staining with ExtrAvidin-Cy3 (Sigma-Aldrich). Luciferase activity
on lung tissue homogenates was measured using a standard lucif-
erase assay kit (Thermo Fisher Scientific) and a 20/20n luminometer
(Turner Biosystems).17,19 The relative light intensity was normalized
by total protein concentration measured by a standard bicinchoninic
acid assay (Thermo Fisher Scientific).
Statistical Analysis
Data were analyzed with statistical tests, including Student’s t test
using SigmaPlot 10.0 and a non-parametric MannWhitney test using
MATLAB R2014b. Multiple comparisons were performed by one-302 Molecular Therapy: Methods & Clinical Development Vol. 9 June 20way ANOVA using MATLAB R2014b. Data were considered
statistically significant when p < 0.05. The statistical tests used in
each dataset are indicated in the figure legends.
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